BIOAVAILABILITY OF URSOCARB VS ACTIGALL IN CHRONIC CHOLESTATIC LIVER DISEASE

$28,540M01FY2000RRNIH

Children'S Hospital Med Ctr (Cincinnati), Cincinnati OH

Investigators

Linked publications & trials

Paper 39586039 Paper 38348682 Paper 37726016 Paper 37607070 Paper 36730995 Paper 36102333 Paper 35728925 Paper 33478957 Paper 33402707 Paper 33038899 Paper 32978526 Paper 32446491 Paper 31996606 Paper 31691959 Paper 31427096 Paper 31337693 Paper 31229956 Paper 31107769 Paper 30772836 Paper 30737489 Paper 30062831 Paper 29872859 Paper 29795315 Paper 29538362 Paper 29369937 Paper 29261644 Paper 28982710 Paper 28953005 Paper 28936131 Paper 28724466 Paper 28710059 Paper 28647272 Paper 28637661 Paper 28562255 Paper 28541083 Paper 28465159 Paper 28434525 Paper 28283553 Paper 28279433 Paper 28199816 Paper 28165634 Paper 27984340 Paper 27776752 Paper 27699249 Paper 27629374 Paper 27509060 Paper 27490775 Paper 27487228 Paper 27458992 Paper 27455401 Paper 27423510 Paper 27398703 Paper 27244849 Paper 27187849 Paper 27131403 Paper 27117196 Paper 26895876 Paper 26719293 Paper 26516117 Paper 26449661 Paper 26419938 Paper 26407251 Paper 26387012 Paper 26348753 Paper 26301688 Paper 26080344 Paper 26046606 Paper 25963007 Paper 25955535 Paper 25838616 Paper 25713280 Paper 25689458 Paper 25683819 Paper 25676588 Paper 25488600 Paper 25464887 Paper 25449221 Paper 25443061 Paper 25434914 Paper 25425651 Paper 25349317 Paper 25170752 Paper 25118269 Paper 25003746 Paper 24934607 Paper 24916553 Paper 24876196 Paper 24812670 Paper 24797288 Paper 24755047 Paper 24739663 Paper 24732104 Paper 24725582 Paper 24685959 Paper 24554564 Paper 24472229 Paper 24446439 Paper 24429845 Paper 24378638 Paper 24370654

Abstract

The objective of this study is to determine the bioavailability of a polymer coated and buffered UDCA (URSOCARB) as compared to ACTIGALL on percent UDCA enrichment in the bile, proportion and concentration of UDCA in serum, and compare the differences between the results for these two treatments in patients with cystic fibrosis and chronic liver disease. Following a four-week treatment with ACTIGALL at 15-30 mg/kg/day (given in two divided doses), the subjects will have samples of bile (string test), blood and urine collected. The subjects will then have a 24-hour wash-out period, and be switched to URSOCARB at 15-30 mg/kg/day (given in two divided doses). At the end of four weeks of treatment, the subjects will have samples of bile (string test), blood and urine collected. The samples of bile will be analyzed for the degree of UDCA enrichment. Serum and urinary excretion will be measured; enhanced renal output of UDCA will support the contention that greater solubility of UDCA in the intestine increases absorption and bioavailability.

View original record on NIH RePORTER →